Novel Candidate Genes for Treatment Response to Antipsychotics in Schizophrenia Schizophrenia is a severe and chronic mental disorder. The lifetime risk of schizophrenia is around 1%. Its course is chronic and frequently disabling. The keystone of schizophrenia treatm...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

3-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals This open-label, non-randomized, prospective study will evaluate the risk of symptoms recurrence during the three years after antipsychotic discontinuation in a sample of functionally reco...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study of the Activation of Proinflammatory Pathways of Toll-like Receptors in Schizophrenia Patients The study of immune pathways involved in the etiopathogeny of schizophrenia would be an important advance to understand the mechanisms involved in the development of this disease and it wo...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up The selection of antipsychotic in early stages of the illness is mainly determined by its clinical effectiveness. Second generation antipsychotics (SGAs) are the first line drug treatment ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up This study compares the efficacy and effectiveness of two of the second-generation antipsychotics (SGAs) most used in our society in the treatment of schizophrenia (Aripiprazole and Risper...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up Cognitive enhancement is a primary goal in treating individuals with schizophrenia. Cognitive deficits are already present at the first break of the illness, seem to remain stable during e...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Cost-effectiveness of Interventions in First-episode Psychosis Schizophrenia has very significant economic consequences. Costs fall on many different parts of society, especially on individuals with schizophrenia and their families. The first five yea...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis The selection of antipsychotic in early stages of the illness is mainly determined by its clinical effectiveness. Second generation antipsychotics (SGAs) are the first line drug treatment ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Longitudinal Long-term Study (10 Years) of the Sample of First Episode of Non-affective Psychosis: PAFIP Schizophrenia is a chronic brain disease that is still understood as a condition that limits the development of a normal life for the patient who suffers it and their families. The idea th...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Impact of Aerobic Exercise on Metabolic Syndrome, Neurocognition and Empowerment in Individuals With Mental Disorders This study aims to develop a program of systematic physical exercise maintained for at least 12 weeks to normalize biomarkers of metabolic syndrome; improve neurocognition and social funct...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune